Effects of methanolic extract and commercial oil of Nigella sativa L. on blood glucose and antioxidant capacity in alloxan-induced diabetic rats

Pteridines

Volumn 18, Issue 1, 2007, Pages 8-18

  Houcher, Zahira ^a   Boudiaf, Khaouther ^a   Benboubetra, Mustapha ^a   Houcher, Bakhouche ^a  

^a FERHAT ABBAS UNIVERSITY   (Algeria)

Author keywords

Alloxan; Diabetes; FRAP; Glucose; Nigella sativa; Osmotic fragility; Oxidative stress

Indexed keywords

ALLOXAN; GLUCOSE; METHANOL; NIGELLA SATIVA EXTRACT;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLACK CUMIN; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; ENZYME INHIBITION; ERYTHROCYTE FRAGILITY; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; LIVER; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

NIGELLA SATIVA; RATTUS;

EID: 34547765546     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2007.18.1.8     Document Type: Article

References (52)

1. Gavin III JR, Alberti KGMM, Davidson MB, et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
2. Kanter M, Meral I, Yener Z, Ozbek H, Demir H. Partial regeneration / proliferation of the ?-cells in the islets of langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. J Exp Med 2003; 201: 213-219.
3. Hayoz D, Ziegler T, Brunner HR, Ruiz J. Diabetes mellitus and vascular lesions. Metabolism, 1998, 47: 16-19.
4. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Dellattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000; 26: 163-176.
5. Marles RJ, Farnsworth NR. Plants as sources of antidiabetic agents. Econ Med Plant Res 1994; 6: 149-187.
6. Broadhurst CL. Nutrition and non-Insulin dependent diabetes mellitus from an anthropological perspective. Alt Med Rev 1997; 2: 378-399.
7. Rchid H, Chevassus H, Nmila R et al. Nigella sativa extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. Fundamental and Clinical Pharmacology 2004, 18: 525-529.
8. Ballero M and Fresu I. Le plante di uso officinale nella Barbagia di Scui (Sardegna Centrale). Fitoterapia 1993, 64:141-150.
9. El-Dakhakhny M. Egyptian Nigella sativa. Arzneimittel-Forsch 1965, 15: 1227-1229.
10. Mahfouz M and El-Dakhakhny M. The isolation of a crystalline active principle from Nigella sativa seeds. J Pharmaceut Sci 1966, 1: 9-19.
11. Toppozada H, Mazloum H, El-Dakhakhny M. The antibacterial properties of Nigella sativa seeds: active principle with some clinical application. J Egypt Med Assoc 1965, 48: 187-202.
12. Mahfouz M, El-Dakhakhny M, Gemei A, Moussa H. Choleretic action of Nigella sativa seed oil. Egyp Pharmacol Bullet 1962, 44: 225-229.
13. El-Kadi A and Kandil O. The black seed (Nigella sativa) and immunity: its effect on human T cell subset. Fed Proc 1987, 46: 1222.
14. Burits M and Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytotherapy Res 2000, 14: 323-328.
15. Worthen DR, Ghosheh OA, Crooks PA. The in vitro anti-tumor activity of some crude and purified components of Black seed Nigella sativa L. Anticancer Res 1998, 18: 1527-1532.
16. Al-Awadi FM, Khattar MA, Gumaa KA. On the mechanism of the hypoglycemic effect of a plant extract. Diabetologia 1985, 28: 432-434.
17. Bamosa A, Ali BA, Sowayan S. Effect of oral ingestion of Nigella sativa seeds on some blood parameters. Saudi Pharmacol J 1997; 5: 126-129.
18. Meral I, Yener Z, Kahraman T, Mert N. Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damaga in experimentally-induced diabetic rabbits. J Vet Med A 2001; 48: 593-599.
19. Mahmood MS, Gilani AH, Khwaja A, Rashid A, Ashfaq MK. The in vitro effect of aqueous extract of Nigella sativa seeds on nitric oxide production. Phytother Res 2003: 17: 921-924.
20. Winkler C, Houcher B, Schroecksnadel K, Schennach H, Fuchs D. Nigella sativa seeds (black cumin) counteract cytokine-induced neopterin production and tryptophan degradation in vitro. Pteridines 2005; 16: 152-153.
21. Houghton PJ, Zarka R, Las Heras B, Hoult JRS. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med 1995, 61: 33-36.
22. Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phyto Res 2004; 18: 195-199.
23. Islam SN, Begun P, Ahsan T, Huque S, Ahsan M. Immunosuppressive and cytotocic properties of Nigella sativa. Phytother Res 2004; 8: 395-398.
24. Mai Le P, Benhaddou-Andaloussi A, Elimadi A, Settaf A, Cherrah Y, Haddad PS. The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat. J Ethnopharmacol 2004; 94: 251-259.
25. Yenson M. Clinical Biochemistry, 6th edn, pp. 365-329. Beta Press Ltd., Istanbul. Yu, B.P., 1994: Cellular defenses against damage from reactive species. Physiol Rev 74: 139-162.
26. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a mesure of "antioxidant power": The FRAP assay. Anal biochem 1996; 239: 70-76.
27. Labhal A, Settaf A, Bennani-Kabchi N, Cherrah Y, Slaoui A, Hassar M. Action anti-obésité, hypocholestérolémiante et hypotriglycéridémiante de Nigella sativa chez le Psammomys obesus. Caducée 1997, 27: 26-28.
28. Labhal A, Settaf A, Zalagh F., Cherrah Y, Hassar M, Slaoui A. Propriétés anti-diabétiques des graines de Nigella sativa chez le Meriones shawi ob?se et diabétique. Espérance Médicale 1999; 47: 72-74.
29. Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol 2002; 79: 23-26.
30. Ouali K, Bairi A, Frih H, Tahraoui A, Guellati MA. Réponses métaboliques et endocriniennes (insulinémie et prolactinémie) ? un stress chronique ? l'éther chez le rat male normal et diabétique. Sci Technol 2003; C(21): 79-84.
31. Surwit RS, Schneider MS, Feinglos MN. Stress and diabetes mellitus. Diabetes Care 1992; 10: 1413-1422.
32. Szkudelski T. The mechanism of alloxan and streptozotocin action in cells of the rat pancreas. Physiol Res 2001; 50: 536-546.
33. Al-Awadi FM, Fatania H, Shamte U. The effect of a plant mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats. Diabetes Res 1991; 18: 163-168.
34. Al-Hader A, Aqel M, Hasan Z. Hypoglycemic effect of the volatile oil of Nigella sativa seeds. Int J Pharmacogon 1993; 1: 96-100.
35. Hedaya SA. Effect of Nigella sativa seeds (black seeds) extract on some heamatologica and biochemical parameters in rats. Alexandria J Vet Sci 1995; 11(2): 95-99.
36. Fararh KM, Atoji Y, Shimizu Y, Shiina T, Nikami H, et Takewaki T. Mechanisms of the hypoglycaemic and immuopotentiating effects of Nigella sativa L. oil in streptozotocin-induced diabetic hamsters. Res Vet Sci 2004; 77: 123-129.
37. Ishikawa Y, Watanabe K, Takeno H, Tani T. Effect of the novel oral antidiabtic agent HQL-975 on oral glucose and lipid metabolism in diabetic db/db mice. Drug Res 1998; 48: 245-250.
38. Hawsawi ZA, Basil AA, Bamosa AO. Effect of Nigella sativa (black seed) and thymoquinone on blood glucose in albino rats. Ann Saudi Med 2001; 21(3-4): 242-244.
39. Al-Awadi FM, Gumaa KA. Studies on the activity of individual plants of an antidiabetic plant mixture. Acta Diabetol 1987, 24: 7-41.
40. El-Naggar AM, El-Deib AM. A study of some biological activities of Nigella sativa (black seeds) "Habat El Baraka". J Egypt Soc Pharmacol Exp Ther 1992, 11: 781-799.
41. Favier A. Le stress oxydant: intéret de sa mise en évidence en biologie médicale et problemes posés par le choix d'un marqueur. Ann Biol Clin 1997; 55: 9-16.
42. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95: 351-358.
43. Sasvári M, Nyakas C. Time dependent changes in oxidative metabolism during chronic diabetes in rats. Act Biol Szegediensis 2003; 47(1-4): 153-158.
44. Leinonen JS, Alho H, Harmoinen A, Lehtimaki T, Knip M. Unaltered antioxidant activity of plasma in subjects at increased risk for IDDM. Free Radic Res 1998; 29: 159-164.
45. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-1014.
46. Opara EC, Abdel-Rahman E, Soliman S, Kamel WA, Souka S, Lowe JE, Abdel Aleem S. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism 1999; 48: 1414-1417.
47. Ceriello A, Russ P, Amstael P, Cerutt P. High glucose induces antioxidants enzymes in humans endothelial cells in culture: Evidence linking hyperglycemia and oxidative stress. Diabetes 1996, 45: 471-477.
48. El-Saleh SC, Al-Sagair OA, Al-Khalaf MI. Thymoquinone and Nigella sativa oil protection against methionine-induced hyperhomocysteinemia in rats. Int J Cardiol 2004; 93: 19-23.
49. Stocker R. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 422-433.
50. Kennedy L, JW Baynes. Non-enzymatic glycolysation and the chronic complications of diabetes: An Overview. Diabetologia 1984; 24: 93-98.
51. Araki K, Rifkind JM. The rate of osmotic hemolysis. A relationship with membrane bilayer fluidity. Biochim Biophys Acta 1981; 645: 81-90.
52. Oldfield E, Chapman D. Dynamics of lipids in membranes: Heterogeneity and the role of cholesterol. FEBS Lett 1972; 23: 285-297.